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patic injury (51, 65) . The pathophysiological implication of increased intracellular bile acid concentrations is illustrated in children with progressive familial intrahepatic cholestasis (PFIC type 2), a disorder marked by progressive hepatic injury due to a mutation in the canalicular bile salt transporter (45) . This mutation leads to the accumulation of bile acids within hepatocytes. Despite the pathological importance of bile saltinduced hepatic injury, the mechanisms behind its toxic effects have not been fully characterized, thus hampering the development of therapeutic strategies to protect against their deleterious effects.
Increases in cAMP protect hepatocytes from apoptosis are due to several stimuli including bile acids, lipopolysaccharide, Fas, and TNF-␣ (16, 22, 25, 67, 71, 80) . Despite cAMP's important role in maintaining hepatocyte health, the downstream signaling events involved in its prosurvival signaling have not been fully characterized. cAMP transduces intracellular signals through three pathways: 1) the serine/threonine protein kinase A (PKA), 2) cAMP-gated channels in the heart and brain, and 3) the cAMP binding guanine nucleotide exchange factors [cAMP-GEFs, also known as exchange proteins regulated by cAMP (EPACs)] (24, 33) . We and others have shown that the cAMP cytoprotection in hepatocytes is, in part, transduced through cAMP-GEF activation (16, 22, 67, 80) . cAMP-GEFs function as GEFs for the small GTPase, Rap (11, 24, 33, 37) . cAMP/cAMP-GEF/Rap signaling pathways exist in hepatocytes, and we have shown that cAMP-GEF activation protects hepatocytes against bile acid-induced apoptosis through activation of phosphoinositide-3-kinase (PI3K)/Akt (16, 22) . The PI3K/Akt signaling is a well-known cellular survival signaling pathway in many cell types including hepatocytes and cholangiocytes (13, 16, 18, 22, 23, 67, 75, 77, 96) . The downstream effector of the cAMP-GEF/PI3K/Akt cytoprotective pathway in hepatocytes, however, has not been determined.
Glycogen synthase kinase-3 (GSK) was initially discovered decades ago as a kinase that reduces glycogen synthase activity. However, it is now known that GSK is a multifunctional kinase, playing a role not only in glycogen metabolism but also in cell proliferation, growth, and death (20, 38, 41, 70) . GSK is constitutively active in resting cells, and phosphorylation results in inactivation. GSK is present as two isoforms, ␣ and ␤. Phosphorylation and inhibition of the GSK3␤ has been implicated in protection from cell death in cardiac myocytes, neurons, and renal epithelial cells (1, 39, 48, 58, 90) . Most recently, inhibition of GSK3␤ activity has been shown to be cytoprotective from acetaminophen, ischemia-reperfusion, endotoxin, and free fatty acid injury in hepatocytes (17, 35, 78, 87) . Several upstream kinases can phosphorylate GSK3␤, including PKA and PI3K/Akt. Thus it is logical to speculate that cAMP cytoprotection in bile acid-induced injury might depend on phosphorylation and inactivation of GSK3␤.
The goal of these studies was to determine whether GSK3␤ inhibition might be the downstream mechanism involved in a cAMP/cAMP-GEF/PI3K/Akt cytoprotective pathway in hepatocytes. Our results indicate that cAMP-GEF activation results in PI3K-dependent phosphorylation of GSK3␤ and that inhibitors of GSK protect hepatocytes from bile acid-induced apoptosis. Protection is accompanied by inhibition of both bile acid-induced phosphorylation of the proapoptotic kinase c-Jun NH 2 -terminal kinase (JNK) and bile acid-mediated endoplasmic reticulum (ER) stress.
MATERIALS AND METHODS
Reagents. Collagenase, Hoechst 33258, glycochenodeoxycholate (GCDC), wortmannin, LY294002, 8-(4-chlorophenylthio)-cAMP (CPTcAMP), tunicamycin, and all tissue culture reagents were purchased from Sigma-Aldrich Chemical (St. Louis, MO). The GSK inhibitors lithium chloride (LiCl), 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrol-2,5-dione (SB415286), and 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) were from Sigma Aldrich Chemical. Additional GSK inhibitors 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD), (2=Z,3=E)-6-bromoindirubin-3=-oxime (BIO), its negative control compound 1-methyl-BIO (ME-BIO), the Src inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2), and its inactive control 4-amino-7-phenylpyrazol [3,4-d] pyrimidine (PP3), the JNK inhibitor 1,3-benzothiazol-2-yl-(2-((2-(3 pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile (AS601645), and antibodies to actin were from EMD Bioscience (San Diego, CA). The cAMP-GEF-specific cAMP analog 4-(4-chlorophenylthio)-2=-Omethyladenosine-3=,5=-cyclic monophosphate (CPT-2-Me-cAMP), the specific PKA inhibitor Rp-8-(4-chlorophenylthio)-cAMP (Rp-CPTcAMP), and Fas ligand were from Axxora (San Diego, CA). The PI3K␥-specific inhibitors, AS604850, was from Calbiochem (San Diego, CA) [ , and pIEF2␣ ser51 and antibodies to cleaved caspase 3 and total Akt, GSK3␤, and BAX were obtained from Cell Signaling Technology (Beverly, MA). Small interfering RNA (siRNA) targeted to human GSK3␤, random oligonucleotide siRNA controls and antibodies to GADPH, Mcl-1 and cytochrome c were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to inositol-requiring enzyme (IRE)-1 ser724 and ␤-catenin were from Abcam (Cambridge, MA). The adenoviral control AD5LacZ and dominant-negative AD5delta-FADD constructs were a generous gift of Dr. David Brennar (University of California San Diego Health Sciences) and have been previously described (10) . The adenoviral control green fluorescent protein (GFP) adenovirus and GFP-tagged Rap1GAP-GFP were provided by Erika Wittchin (University of North Carolina at Chapel Hill) (95) .
Cell cultures. Primary rat hepatocytes were isolated from male Wistar rats (200 -250 g) as previously described (16, 22) . Hepatocytes were plated at 5 ϫ 10 5 cells/cm 2 on tissue culture dishes or coverslips coated with type I rat tail collagen in minimal Eagle's medium (MEM) with L-glutamine, 100 nM insulin, and 10% heat-inactivated fetal calf serum and incubated at 37°C in a humidified atmosphere of 5% CO 2 for 1 h. Medium was changed to MEM without supplements and, after an additional 3 h, apoptosis was initiated by the addition of 50 M GCDC, 50 ng/ml Fas ligand or 2 g/ml tunicamycin. Unless otherwise noted, modulators were added at the indicated concentration 30 min prior to the addition of the apoptotic stimulus. All animals received humane care according to the criteria outlined in the "Guide for the Care and use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health, and all animal study protocols were submitted to and approved by an institutional animal use and care committee.
HUH7-NTCP cells, a human hepatoma cell line, that stably overexpresses the human bile salt transporter were a generous gift of Dr. Greg Gores (Mayo Clinic, Minneapolis, MN) (30) . The cells were cultured in Eagle's minimum essential medium supplemented with 10% fetal bovine serum, 100,000 U/l penicillin, 100 mg/l streptomycin, and 0.5 g/ml of genistein at 37°C in a 5% CO 2-95% O2 air incubator. For experiments, cells were serum starved overnight and then treated with 200 M GCDC for 3-4 h. Modulators were added 30 min prior to GCDC.
Assessment of apoptosis. Morphological evaluation of apoptotic cell death in rat hepatocytes was conducted 2 or 4 h after the addition of GCDC or tunicamycin or Fas ligand and 4 h after the addition of GCDC to HUH7-Ntcp cells as previously described (16, 22) . Briefly, coverslips were stained with Hoechst 33258 and apoptosis was evaluated with fluorescent microscopy. Apoptotic cells were identified as those whose nucleus exhibited brightly staining condensed chromatin or nuclear fragmentation. Five hundred cells were counted by an observer blinded to the treatment conditions and the number of apoptotic cells was expressed as a % of the total number of cells counted. The presence of the p17-kDa cleavage product of caspase 3 was used as a biochemical indicator of hepatocyte apoptosis. Cell lysates were prepared from hepatocytes treated with GCDC (2 h) or Fas (4 h) in cell lysis buffer, 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mm EGTA, 1% Triton, 2 mM EDTA, 2.5 mM sodium pyrophosphate, 1 mM glycerolphosphate, 1 mM phenylmethylsulfonyl fluoride, 100 nM okadaic acid, 1 mM sodium orthovanadate, and 10 g/ml of leupeptin, aprotinin, and pepstatin, separated on SDS-PAGE, and the proteins were transferred to polyvinylidene difluoride (PVDF) membranes. Immunoblotting was performed with a caspase 3 antibody and equal protein loading was verified by stripping and probing with an actin antibody.
Determination of kinase phosphorylation. Rat hepatocytes or HUH7-Ntcp cells were treated with indicated bile acids for 60 min in with and without prior treatment with 20 M CPT-2-Me-cAMP or with the indicated concentrations of GSK or PI3K␥ inhibitors for 30 min. Cells were lysed in ice-cold cell lysis buffer and equal amounts of protein were separated in SDS-PAGE, transferred to PVDF membranes and probed with antibodies Akt Ser473 , JNK Thr183/Tyr185 , GSK3␤ ser9 , pIEF2␣ ser51 , or IRE-1 ser724 . Membranes were developed with chemiluminescence after incubation with a peroxidase-conjugated second antibody. Stripped membranes were reprobed with antibodies for the unphosphorylated form of the kinase or with actin or GADPH to verify equal protein loading. Blots were digitalized and subjected to densitometric analysis. Transfections.
HUH7-NTCP cells at 40 -50% confluency were transfected with 50 nmol/l of a control siRNA or siRNA targeted to GSK3␤ by using Lipofectamine (Invitrogen, Carlsbad, CA) according to manufacturer's instructions. Cells were used for experiments 48 h later. Downregulation of GSK3␤ was verified by immunoblot analysis. For adenoviral studies primary hepatocytes were transfected in serum-free media for 2 h with gentle rocking at a multiplicity of infection of 10. The cells were cultured overnight in MEM, exposed to 100 M GCDC or 50 ng/ml Fas ligand, and analyzed morphologically and biochemically for the presence of apoptosis as described above.
Preparation of mitochondrial and cytosolic fractions. Cytosolic and mitochondrial fractions were prepared from rat hepatocyte cultures treated for the indicated times with GCDC, as previously described (93) , with slight modifications. Briefly, cells were scraped in mannitol-sucrose buffer [200 mM mannitol, 70 mM sucrose, 1 mM EGTA, and 10 mM HEPES (pH ϭ 7.5) supplemented with 200 mM dithiothreitol, 0.1 mM PMSF, and 10 g/ml leupeptin, pepstatin, and aprotinin] and then Dounce homogenized. The homogenate was spun at 400 g to remove nuclear debris. The supernatant was spun again at 10,000 g, and the pellet, which represented the mitochondrial fraction, was resuspended in mannitol-sucrose buffer containing 1% Nonidet P-40. The supernatant from the mitochondrial spin was centrifuged at 100,000 g, and the supernatant from this high-speed spin was saved as the cytosolic fraction.
Mitochondrial and cytosolic fractions were also prepared by a selective digitonin permeabilization as originally described by Leist et al. (46) and modified by Higuchi et al. for hepatocytes (32) . This protocol was used to avoid possible artifacts due to potential mechanical breakage of the outer mitochondrial membrane of apoptotic cells by Dounce homogenization and to facilitate experiments in which multiple treatments were required. Briefly, at the desired time points, the culture medium was replaced with permeabilization buffer (210 mm D-mannitol, 70 mm sucrose, 10 mm HEPES, 5 mm succinate, 0.2 mm EGTA, 0.15% bovine serum albumin, 80 g/ml digitonin, pH 7.2). The cells were incubated in this buffer for 5 min on ice and then centrifuged for 10 min at 13,000 g. The supernatant was saved as the cytosolic extract. Pellets were washed three times with ice-cold PBS, centrifuged, and solubilized in digitonin buffer with 1% Triton X-100 and used as the mitochondrial fraction. Purity of the fractions was determined by immunoblotting the cytosolic and mitochondrial preparations with the mitochondrial protein anti-cytochrome c oxidase (ACCO; Molecular Probes, Eugene, OR) or the cytosolic protein GADPH (Santa Cruz Biotechnology), respectively. The mitochondrial release of cytochrome c in cytosolic fractions and the movement of Bcl-2 like proteins to the mitochondria was monitored by immunoblotting. Cytosolic and mitochondrial proteins (30 g) were separated on SDS-PAGE, transferred to nitrocellulose, and immunoblotted with antibodies to cytochrome c, GADPH, ACCO, BAX, or Mcl-2.
To validate this technique, we compared the preparation of mitochondrial membranes using this method to standard subcellular fractionization techniques. Since we have previously demonstrated that treatment of hepatocytes with GCDC results in translocation of BAX to the mitochondria using the subcellular fractionization method, we did side-by-side experiments comparing the amount of BAX in mitochondrial fractions prepared by both methods at different points after treatment of rat hepatocytes with GCDC. The results show that both techniques give almost identical results (Fig. 1) . To further verify the integrity of the digitonin technique we immunoblotted mitochondrial and cytosolic fractions with GAPDH and cytochrome c oxidase. These studies showed that the mitochondrial fractions prepared by digitonin permeabilization were clear of the cytosolic marker GADPH and enriched in the mitochondrial marker ACCO (Fig. 1) .
Bile acid uptake. The 30-min accumulation of radiolabeled bile acid, [ 3 H]taurocholate (Perkin Elmer, Boston, MA), in hepatocyte cultures was determined as previously described (16) .
Statistical evaluation. All results are expressed as means Ϯ SD of at least three separate experiments. Results were analyzed for statistical significance with Student's t-test or one-way ANOVA. A P value of Ͻ 0.05 was considered significant.
RESULTS

PKA-and PI3K-dependent phosphorylation of GSK3␤ by
cAMP. GSK3␤ can be phosphorylated and thus inactivated by a number of kinases including PKA and PI3K/Akt (20, 41, 70) . Since cAMP can activate both PKA and PI3K/Akt in hepatocytes (16), we hypothesized that cAMP might phosphorylate GSK3␤ via this pathway. We have previously demonstrated that the CPT-cAMP analog activates both PKA and cAMPGEFs, whereas CPT-2-Me-cAMP is specific for cAMP-GEF activation (16) . Thus we studied the effect of both CPT-cAMP and CPT-2-Me-cAMP to determine the effects mediated via PKA and cAMP-GEF. Time course studies showed that CPTcAMP caused a rapid (within 2 min) and sustained phosphorylation (60 min) of GSK3␤ whereas CPT-2-Me-cAMP caused a more gradual and transient rise in GSK3␤ phosphorylation ( Fig. 2A) . To determine the kinase responsible for cAMPmediated GSK3␤ phosphorylation, we pretreated cultures with the PI3K/Akt inhibitors Ly294002 or wortmannin or the PKA inhibitor Rp-cAMP for 30 min prior to addition of the cAMP analogs. The PI3K/Akt and PKA inhibitors each decreased CPT-cAMP-induced GSK3␤ phosphorylation by 40 and 50%, respectively ( Fig. 2B) , indicating that the effect of CPT-cAMP is mediated via both PI3K/Akt and PKA. On the other hand, PI3K/Akt inhibitors completely blocked GSK3␤ phosphorylation in response to CPT-2-Me-cAMP ( Fig. 2C ) whereas the PKA inhibitor had no effect (data not shown). Thus cAMP-GEF-mediated phosphorylation GSK3␤ is mediated entirely through PI3K/Akt.
To verify that cAMP-GEF activation and use of the GSK inhibitors were associated with inhibition of GSK, we examined the effect of these treatments on the downstream GSK substrate ␤-catenin. In the basal state when GSK is constitutively active and unphosphorylated, ␤-catenin is phosphorylated (61) . Phosphorylated ␤-catenin is targeted for degradation by the proteosome and the ␤-catenin that remains in the cell is primarily localized in the membrane/cytoskeleton. When A: rat hepatocytes were solubilized with digitonin as indicated in MATERIALS AND METHODS to isolate a digitoninsoluble fraction (called cytosol) and a digitonin-resistant fraction that was subsequently solubilized in Triton X-100 (mitochondria). Equal aliquots of each preparation were immunoblotted with the cytosolic marker protein GADPH and the mitochondrial marker cytochrome c oxidase (ACCO). B: rat hepatocytes were treated with glycochenodeoxycholate (GCDC) for the indicated times and then a mitochondrial fraction was prepared by either subcellular fractionization (SCF) or selective digitonin permeabilization (Dig Perm). Then the amount of the proapoptotic protein, BAX, in each mitochondrial fraction was determined by immunoblotting. *Amount is significantly different than that in control untreated cultures.
GSK3␤ is inactivated ␤-catenin is dephosphorylated and protected from degradation. Thus protein expression increases and ␤-catenin moves into the cytoplasm and nucleus. Therefore treatment with cAMP-GEF, GSK inhibitors, or insulin, all of which inactivate GSK, should lead to an increase in cytosolic ␤-catenin. When we treated rat hepatocytes with the cAMP analogs or GSK inhibitors we observed a modest (ϳ30%) but significant increase in the expression of ␤-catenin in whole cell lysates (Fig. 3) . However, there was a substantial increase (3-to 6-fold) in the amount of cytosolic ␤-catenin with all treatments (Fig. 3) .
In a previous study we showed that the activation of PI3K/Akt pathway by cAMP-GEF is dependent on Src and epidermal growth factor receptor (EGFR) activity (22) . To determine whether cAMP-GEF/Src/EGFR/PI3K/Akt pathway is involved in GSK3␤ phosphorylation, we tested the effect of the EGFR inhibitor AG1478 and the Src inhibitor PP2 and its inactive analog PP3 on cAMP-GEF-stimulated GSK3␤ phosphorylation. Both PP2 and AG1478 inhibited CPT-2-Me-cAMP-mediated phosphorylation of GSK3␤ (Fig. 2D) . These results suggest that GSK3␤ phosphorylation involves a cAMP-GEF/Src/EGFR/PI3K/Akt/ GSK3␤ pathway and raises the possibility that this pathway may be involved in the cytoprotective effect of cAMP against GCDCinduced apoptosis.
We have previously demonstrated that the compounds we used to inhibit kinase activity upstream of GSK3␤, namely wortmannin, RP-cAMP, LY294002, PP2, and AG1478, do indeed inhibit their target kinases in rat hepatocytes (16, 22, 34, 93) .
cAMP-GEF-mediated PI3K/Akt/GSK3␤ phosphorylation and hepatocyte cytoprotection are Rap1 dependent. We had previously shown that cAMP-GEF activation in hepatocytes leads to activation of both Rap1 and Rap2 (16, 22) . Although Rap1 and Rap2 share structural homology, they are not functionally redundant (11, 33, 37) . To determine which isoform is necessary for cAMP-GEF-mediated PI3K/Akt phosphorylation and hepatocyte cytoprotection, we used an adenoviral Rap1GAP construct that prevents GTP loading of Rap1 to inhibit Rap1 activity (93) . Transfection with Rap1GAP attenuated both the cytoprotective effect of CPT-2-Me-cAMP in bile acid-induced apoptosis (Fig. 4A ) and the ability of the analog to phosphorylate Akt and GSK3␤ (Fig. 4B) . These results suggest that Rap1 activation is necessary for cAMP-GEF PI3K/Akt/GSK3␤-mediated cytoprotection from bile acid-induced apoptosis.
GSK inhibition protects against GCDC-induced apoptosis. The next series of studies were conducted to determine the role of GSK in GCDC-induced apoptosis. If cAMP-GEF/Src/ EGFR/PI3K/Akt/GSK3␤ pathway is involved in the cytoprotective effect of cAMP, inhibition of GSK3␤ should reverse GCDC-induced apoptosis. This hypothesis was tested by determining the effect of chemical inhibitors of GSK on GCDCinduced apoptosis. To ensure the specificity of our observations, we utilized several structurally distinct GSK inhibitors with different modes of action. BIO and the SB compounds (SB216763 and SB415286) are indirubin-3=-oxime and maleimide derivatives, respectively, that inhibit GSK in an ATPcompetitive manner (5, 14, 15, 53, 81) . ME-BIO is a methylated inactive analog of BIO. LiCl is the classic, although somewhat nonspecific, GSK inhibitor, which works in an ATP-noncompetitive manner. The thiadiazolidinone TDZD is also a non-ATP-competitive inhibitor that exhibits specificity for the GSK3␤ isoform (66) . Its inhibitory activity is due to covalent modification of a cysteine residue in GSK3␤ ATP binding site.
Pretreatment with either BIO or SB415286 attenuated morphological (Hoechst staining) and biochemical (cleavage of caspase 3) evidence of GCDC-induced apoptosis (Fig. 5, A, C,  E, and F) . There was no additional protective effect when the cAMP-GEF analog, CPT-2-Me-cAMP, was combined with either of these GSK inhibitors (Fig. 5, A and C) , indicating a common pathway. The GSK inhibitors (BIO, ME-BIO, or SB415286) alone had no effect on baseline apoptosis (data not shown). The other GSK inhibitors SB216763, TDZD, and LiCl (Fig. 5 , B, D-F) also attenuated GCDC-induced apoptosis. Thus it appears that active GSK3␤ is necessary for GCDCinduced apoptosis and that inactivation of GSK3␤ is a putative downstream effector in the cAMP-GEF/PI3K/Akt cytoprotective pathway.
To determine whether the effect of GSK inhibition extended to human liver cells, we investigated the effect of GSK inhibition on GCDC-induced apoptosis in the HUH7-NTCP cell line. We and others have previously used the HUH7-Ntcp cell line, a model system that is amenable to genetic manipulation, to study GCDC-induced apoptosis (34, 74, 76) . First, we verified that the cAMP-GEF analog, CPT-2-Me-cAMP, was cytoprotective in HUH-NTCP cells and that it induced PI3K and Src kinase-dependent phosphorylation of GSK3␤ (Fig. 6,  A and B) . Thus HUH-NTCP cell line was considered to be an appropriate model. Next we showed that GSK inhibitors were cytoprotective. BIO attenuated GCDC-induced apoptosis whereas the inactive analog, ME-BIO, had no effect (Fig. 6C) . Similar inhibition of GCDC apoptosis was obtained by pretreatment with SB415286, SB 216786, TDZD, and LiCl (Fig.  6D) . None of the GSK inhibitors themselves had any effect on the baseline level of apoptosis in HUH7-NTCP cells (data not shown). The above studies with GSK inhibitors suggest that inhibition of GSK leads to cytoprotection against GCDCinduced apoptosis. However, these results do not necessarily suggest that the effect is mediated via GSK3␤ isoform. Although BIO, SB216763, SB415286, and LiCl inhibit both the ␣ and ␤ isoforms of GSK, TDZD is more specific for the ␤ isoform. Thus our results showing that TDZD inhibited GCDC apoptosis in rat hepatocytes and HUH7-NTCP cells suggest that it is the phosphorylation (inhibition) of GSK3␤ that may be involved in the cytoprotective effect. To test this hypothesis more directly, we determined the effect of GSK3␤ knockdown on GCDC-induced apoptosis. This was done only in the HUH7-NTCP cells because siRNA knockdown of GSK3␤ requires at least 48 h. In this time frame, primary hepatocytes in culture lose the expression of bile salt transporter and thus are resistant to bile acid-induced apoptosis. Transfection with siRNA to GSK3␤ resulted in a decrease in the level of GSK3␤ by ϳ60% by 48 h (Fig. 6E, inset) . Apoptosis in response to GCDC in the GSK3␤ siRNA-but not scrambled siRNAtransfected cells was significantly attenuated (Fig. 6E) . Collectively these results suggest that inhibition of GSK3␤ is necessary for cytoprotection against GCDC-induced apoptosis. Since cAMP-GEFs inhibits GSK3␤, it is highly likely that the cytoprotective effect of cAMP-GEFs against GCDC-induced apoptosis is mediated via inhibition of GSK3␤.
As we have previously shown that cAMP-GEF activation protects against death receptor-mediated apoptosis stimulated by ligation of the Fas receptor (22) , if we hypothesize that the protective effect of cAMP-GEF is mediated by GSK phosphorylation, then direct chemical inhibition of GSK should also attenuate Fas ligand-mediated apoptosis. To test this hypothesis we pretreated rat hepatocytes with BIO, Me BIO, SB216763, or TDZD prior to exposure to Fas ligand. Fas ligand-induced apoptosis in hepatocytes (20 Ϯ 2.4%) and BIO (13 Ϯ 3.4%), SB216763 (12.5 Ϯ 1.8%), and TDZD (14 Ϯ 2.9%). significantly attenuated this apoptosis (P Ͻ 0.05), supporting our observation that the cAMP-GEF survival effect may involve GSK3␤ phosphorylation.
GSK inhibition attenuates GCDC-induced JNK activation. The mechanism by which inhibition of GSK3␤ leads to cytoprotection against GCDC is not known. Recent studies demonstrated that the protective effect of GSK3␤ inhibition in hepatocytes was associated with attenuation of acetaminophen and fatty acid-induced JNK phosphorylation (35, 78) . Several studies have shown that bile acids induce sustained phosphorylation of JNK in hepatocytes and that chemical or genetic inhibition of this activation attenuates bile acid-induced apoptosis (25, 26, 34, 56, 69, 72) . This observation coupled with our data from previous studies showing that cAMP-GEF activation can attenuate lipopolysaccharide-induced JNK phosphorylation in hepatocytes (67) led us to hypothesize that cAMP-GEFinduced cytoprotection against GCDC-induced apoptosis may be due to GSK3␤ inhibition of GCDC-induced JNK activation. The following studies were conducted to test this hypothesis.
We have recently demonstrated that chemical inhibition of JNK with SP600125 prevents GCDC-induced apoptosis (34) . However, this inhibitor is somewhat nonspecific for JNK (3) and can interfere with bile acid uptake into hepatocytes (data not shown). Thus to confirm the role of JNK we tested the effect of a more specific JNK inhibitor, AS601245, on bile acid uptake and GCDC-induced apoptosis in hepatocytes (12) . Results show that AS601245 prevents morphological and biochemical evidence of apoptosis in primary rat hepatocytes after exposure to GCDC (Fig. 7, A and B) and has no effect on bile acid uptake (data not shown), confirming GCDC-induced apoptosis requires JNK activation.
Next, we determined whether activation of cAMP-GEF affects GCDC-induced JNK phosphorylation. Activation of cAMP-GEFs by CPT-2-Me-cAMP inhibited GCDC-induced JNK phosphorylation without affecting basal level of JNK phosphorylation (Fig. 7, C and D) , raising the possibility that this inhibition may be-mediated via cAMP-GEF-mediated inhibition of GSK3␤. This possibility was tested by studying the effect of GSK inhibitors on GCDC-induced JNK phosphorylation. All of the GSK inhibitors tested (SB216763, SB415286, and BIO) attenuated GCDC-induced JNK activation in hepatocytes (Fig. 7, E and F) , indicating that inhibition of GSK3␤ leads to inhibition of GCDC-induced JNK activation. Taken together, these results are consistent with our hypothesis that cytoprotection against GCDC-induced apoptosis involves cAMP-GEF-induced inhibition of GSK3␤ followed by inhibition of GCDC-induced JNK activation.
GSK inhibition prevents GCDC-induced mitochondrial-mediated apoptosis.
Although previous studies have suggested that bile acid-induced apoptosis is mediated via death receptor signaling (51) , accumulating data support a more prominent role for the intrinsic apoptotic pathway in bile acid injury. This evidence includes the observations that 1) hepatocytes from mice lacking death receptors or Bid still undergo death in vivo after bile duct ligation or in culture after exposure to bile acids despite blockage of death receptor pathways and 2) blockage of ser9 phosphorylation was determined in cell lysates. HUH7-NTCP cells were pretreated with the GSK inhibitor BIO (10 M) or it inactive control analog ME-BIO (10 M) (C) or with SB415286 (25 M), SB216746 (10 M), or TDZD (25 M) (D) and then exposed to GCDC (200 M) for 3 h. Apoptosis was determined by morphological evaluation of Hoechst-stained cells. E: HUH7-NTCP cells were transfected with small interfering RNA (siRNA) to GSK3␤ or a scrambled siRNA (siRNA SCRB) for 48 h and then exposed to GCDC for 4 h, and the percent apoptosis was determined morphologically. *Significantly different than GCDC (A, C-E)-or CPT-2-Me-cAMP (B)-treated cells. death receptor signaling with genetic inactivation of the Fasassociated protein with death domain (FADD) has no effect on bile acid-induced apoptosis in both rat hepatocytes and human hepatoma cells (17, 31, 59, 69, 74, 76) . FADD is an adaptor molecule that bridges death receptors to caspase-8 and is required for execution of apoptosis by all known death receptors.
To further address this controversy and to determine how bile acid injury proceeds in our experimental model, we examined the effect of transfection with an adenoviral dominantnegative FADD construct on GCDC and Fas ligand-induced apoptosis in rat hepatocytes. Adenoviral transfection of rat hepatocytes with a dominant-negative FADD construct had no effect on GCDC-induced apoptosis but totally blocked Fas ligand-mediated apoptosis (Fig. 8, A and B) . Furthermore, transfection of dominant-negative FADD had no effect on proapoptotic phosphorylation of JNK by bile acids but inhibited Fas-mediated JNK phosphorylation (Fig. 8C) . This suggests that bile acid-induced apoptosis in our hepatocyte cultures is mediated primarily by a death receptor independent pathway.
Consistent with our demonstration of the importance of mitochondrial dysfunction in bile acid-induced apoptosis, we noted that the treatment of rat hepatocytes with GCDC was accompanied by the release of cytochrome c from the mitochondria (Fig. 8D) . Pretreatment with CPT-2-Me-cAMP or the GSK inhibitors BIO or SB216763 prevented GCDC release of cytochrome c (Fig. 8D) . These studies suggest that the protective effect of cAMP-GEF activation and/or GSK inhibition is associated with stabilization of mitochondrial function.
The protective effect of GSK3␤ inhibition on apoptosis in cardiac myocytes and neurons can be mediated by regulation of Bcl-2 proteins. In these cells GSK3␤ inhibition can prevent proteosomal degradation of the antiapopototic Bcl-2 protein Mcl-1 and inhibit the translocation of the proapoptotic Bcl-2 protein BAX to the mitochondrial membrane (49, 52, 64) . We and others have previously shown that bile acid-induced apoptosis is accompanied by movement of BAX to the mitochondria, and a recent study has demonstrated that genetic knockdown of BAX inhibits bile acid-associated apoptosis (73, 93, 98) . Thus we hypothesized that cAMP-GEF activation might protect against bile acid-induced apoptosis by modulating mitochondrial levels of BAX or Mcl-1. To test these hypotheses, we pretreated hepatocytes with CPT-2-Me-cAMP or BIO and then with GCDC for 1 h and then prepared mitochondrial fractions using the digitonin permeabilization method. Our results show that GCDC treatment translocates BAX to the mitochondrial membrane, but pretreatment with CPT-2-MecAMP or BIO had no effect on this translocation event (Fig. 9,  A and B) . However, we saw no effect on the mitochondrial levels of Mcl-1 after GCDC treatment or following pretreatment of hepatocytes with BIO or CPT-2-Me-cAMP (Fig. 9C ). These results demonstrate that GSK inhibition of bile acidinduced apoptosis is not associated with changes in the mitochondrial expression of BAX or Mcl-1.
cAMP activation and GSK inhibitors blunt bile acid-induced ER stress in rat hepatocytes. Since bile acid can initiate ER stress in hepatocytes (6, 9, 54, 83, 86) and ER stress can lead to JNK activation (50, 79), we examined the role of ER stress in bile acid apoptosis and JNK phosphorylation in rat hepatocytes. ER stress is associated with initiation of the unfolded protein response which is mediated by transmembrane protein sensors including inositol-requiring enzyme (IRE-1) and RNAdependent protein kinase-like ER kinase. The latter phosphorylates and inactivates peIF2␣. To determine whether bile acids-induced ER stress in our cultures, we looked at the phosphorylation of peIF2␣ ser51 and IRE-1 ser724 as indicators of ER stress. Treatment with the hydrophobic bile acids GCDC, taurochenodeoxycholate, or taurolithocholate, but not with the hydrophilic and nontoxic bile acids tauroursodeoxycholate or taurocholate, caused an increase in phosphorylation of both peIF2␣ and IRE-1 (Fig. 10, A-C, F) . GCDC-induced phosphorylation of both compounds was inhibited by pretreatment with CPT-2-Me-cAMP or SB216763. Further evidence for a Fig. 8 . Bile acid-induced apoptosis and JNK activation in rat hepatocytes is death receptor independent. Rat hepatocytes were transfected with an adenoviral control AD5LacZ and dominant-negative AD5delta-FADD construct and then treated with GCDC (50 M), deoxycholate (DCA, 100 M) for 2 h, or Fas ligand (Fas L; 50 ng/ml) for 4 h. Apoptosis was monitored morphologically by examination of Hoechst-stained cells (A) or biochemically by immunoblotting for CLV3 (B). Cont, control. Equal protein loading was verified by immunoblotting for actin. The amount of phosphorylated JNK thr183,tyr185 was determined by immunoblotting (C). D: rat hepatocytes were pretreated with CPT-2-Me-cAMP (20 M), BIO (10 M), or with SB216763 (10 M) and then exposed to GCDC for 2 h. Cytosolic fractions were prepared by subcellular fractionization as described in MATERIALS AND METHODS. The amount of cytochrome c (CYTO C) released into cytosol was determined by immunoblotting. *Significantly different than in the presence of GCDC.
role of GSK in preventing ER stress apoptosis comes from our observation that both the CPT-2-Me-cAMP analog and SB216763 attenuate tunicamycin-mediated hepatocyte apoptosis by 75 and 90%, respectively (data not shown). Tunicamycin inhibits protein glycosylation and is frequently used to induce ER stress.
As we have previously shown that bile acid-induced activation of JNK proceeds through selective activation of PI3K␥ (34), we tested the effect of PI3K␥ inhibitor AS604850 on bile acid-induced ER stress (Fig. 10, D and E) . These results show that inhibition of PI3K␥ attenuates bile acid-induced phosphorylation of both peIf2␣ and IRE-1.
Collectively our results suggest that bile acids activate an ER stress response in hepatocytes and that cytoprotection due to GSK or PI3K␥ inhibition is accompanied by attenuation of these phosphorylation events.
Effect of modulators on bile acid uptake. None of the inhibitors used in these studies (10 M SB216763, 25 M SB415286, 10 M BIO, 10 M Me-BIO, 40 M TDZD, 5 M AG1478, or 5 M AS610245) had any effect on the accumulation of radiolabeled taurocholate in rat hepatocytes (data not shown). We have previously documented that the cAMP analogs and the Src, EGF receptor, and PI3K inhibitors have no effect on bile acid uptake (16, 22) .
DISCUSSION
Previously we have shown that cAMP protects hepatocytes from bile acid-induced apoptosis through a cAMP-GEF/PI3K/ Akt pathway (16, 22) . The present studies were designed to provide additional mechanistic insight into this survival pathway by delineating its downstream mediator and the site in the apoptotic pathway it intercepts. Our studies show that 1) cAMP phosphorylates GSK3␤ by PKA-and PI3K-dependent mechanisms and that the latter is associated with specific activation of cAMP-GEF, 2) genetic or chemical inhibition of GSK3␤ with known GSK inhibitors or by activation of cAMP-GEFs protects rat hepatocytes and/or human hepatoma cells from apoptosis due to cytotoxic bile acids, 3) cAMP-GEF cytoprotection and PI3K/Akt/GSK3␤ phosphorylation is Rap1 dependent, and 4) GSK inhibition or activation of cAMP-GEFs prevent bile acid-induced phosphorylation of the proapoptotic kinase JNK that is accompanied by concurrent attenuation of bile acid-induced phosphorylation of the ER stress markers peIF2␣ and IRE-1.
We have previously demonstrated the presence of a cAMPcAMP-GEF/PI3K/Akt signaling pathway in hepatocytes (16, 22) . This signaling pathway is not unique to hepatocytes; others have demonstrated its presence in cardiac and skeletal muscle, pancreatic ␤ cells, neurons, macrophages, and mesangial cells (4, 43, 44, 55, 60, 62, 97) . The present studies now establish GSK3 as a downstream substrate in this pathway in hepatocytes. We show that cAMP phosphorylates GSK3␤ and that this phosphorylation occurs through both cAMP/PKA-and cAMP/cAMP-GEF/PI3K-dependent pathways. The finding that cAMP phosphorylates GSK3 through PKA mechanism has been demonstrated in nonhepatic cells, but ours is the first demonstration that cAMP can also phosphorylate GSK3␤ in a cAMP-GEF/PI3K-dependent manner.
Our prior studies demonstrate that activation of a cAMP-GEF/PI3K/Akt signaling pathway is associated with cell survival (16, 22) . Several observations in the present studies suggest that GSK3␤ is also a downstream effector in this survival pathway. First, we demonstrate that multiple structurally and functionally distinct chemical inhibitors of GSK3 protect rat hepatocytes and human hepatoma cells from bile acid-induced apoptosis. As GSK3 is constitutively active under resting conditions and phosphorylation on ser9 results in inactivation, specific activation of cAMP-GEFs that phosphorylate GSK would be expected to also inhibit GSK3. Since we have demonstrated that direct GSK3 inhibition is cytoprotective, this ability of cAMP-GEF activation to inhibit GSK would be expected to be cytoprotective as well. Further support for a role of GSK in cAMP-GEF cytoprotection comes from the finding that there is no additional protective effect when cAMP-GEF activation is coupled with direct chemical inhibition of GSK. Finally, we demonstrate that cAMP-GEF-mediated GSK3␤ phosphorylation is sensitive to Src tyrosine kinase and EGFR kinase inhibition, similar to our observations with the cAMP-GEF/PI3K/Akt cytoprotective pathway (22) .
GSK3 exists in two isoforms encoded by separate genes, GSK3␣ and GSK3␤. Although structurally related, the isoforms are not functionally equivalent, with most studies implicating the GSK3␤ isoform in cell survival (39, 41, 58, 70) . Our data showing that protection occurs with the relatively specific GSK3␤ inhibitor, TDZD, in rat hepatocytes and with siRNA to GSK3␤ in human hepatoma cells suggest that it is the ␤ isoform that is important for its protective action.
In nonhepatic cells the survival effect of GSK3␤ inactivation is mediated through several mechanisms including inactivation of proapoptotic kinase JNK, regulation of Bcl-2 proteins, and inhibition of the mitochondrial membrane permeability transition (39, 52, 58, 82) . Less is known in hepatocytes about the cytoprotective action of GSK inactivation. Silencing of GSK3␤ has been associated with inhibition of acetaminophen and fatty acid-mediated JNK activation and cell death (35, 78) . The role of JNK as a proapoptotic kinase in bile acid-induced apoptosis is well established. Several studies show that cytotoxic bile acids result in sustained phosphorylation of JNK and that chemical or genetic inhibition of JNK can attenuate bile acid-induced apoptosis (25, 26, 56, 69, 72) . In these studies we now demonstrate that inhibition of GSK with chemical inhibitors or by phosphorylation by cAMP-GEF inhibits GCDC from phosphorylating JNK. Since direct inhibition of JNK protects hepatocytes from bile acid apoptosis, it is likely that GSK3␤ inhibition of GCDC-induced JNK phosphorylation is important in hepatocyte cell survival. A recent study demonstrating that GSK inhibition attenuates lipoapoptosis in hepatocytes verifies the importance of this signaling pathway in hepatocyte survival (35) .
The mechanism through which bile acids cause induce sustained phosphorylation of JNK is not fully understood. Bile acids can induce ER stress in hepatocytes (6, 9, 54, 83, 86) , and ER stress is known to result in phosphorylation of JNK (50, 79) . Our demonstration that hydrophobic cytotoxic but not hydrophilic cytoprotective bile acids result in phosphorylation of peIF2␣ and IRE-1, two mediators of the unfolded protein response in the ER (50, 79) , suggests that ER stress may be involved in bile acid toxicity. Further support for a role of ER stress comes from our observation that cytoprotection by cAMP-GEF activation or GSK inhibition blocks GCDC-induced phosphorylation of these markers. Recently we presented evidence that JNK activation by cytotoxic bile acids proceeds through the isoform-specific activation of PI3K␥ (34) . Cytotoxic bile acids, but not cytoprotective bile acids, preferentially activate PI3K␥ and chemical or genetic inactivation of PI3K␥ promotes hepatocyte survival after exposure to toxic bile acids (34) . As our present studies show that PI3K inhibition blocks bile acid-induced ER stress, it is tempting to speculate that the cytotoxic bile acid/PI3K␥ pathway proceeds through ER stress-mediated phosphorylation of JNK. In the pancreas, bile acid activation of PI3K␥ blocks sarco(endo)plasmic reticulum Ca 2ϩ -ATPase, causing calcium depletion in the ER, a known stimulus for ER stress (19) . Experiments are underway to determine the exact mechanism whereby a bile acid/PI3K␥ may stimulate ER stress in hepatocytes.
GSK3␤ also modulates apoptosis by controlling mitochondrial Bcl-2 proteins. GSK inactivation prevents the phosphorylation of the antiapoptotic protein Mcl-1 and thus precludes the protein from being targeted for degradation (52) . Sine we failed to see any change in mitochondrial levels of Mcl-1 after cAMP-GEF activation or GSK inhibition, modulation of this protein is an unlikely downstream effector in a cAMP-GEF/ GSK3␤ survival pathway. In neurons, GSK inactivation can lead to phosphorylation of the proapoptotic Bcl-2 effector protein BAX, which in turn prevents BAX's translocation to the mitochondria (49). Although we and others have demonstrated that GCDC-induced apoptosis is associated with translocation of BAX to the mitochondria (73, 93) , in these studies reported in this manuscript we failed to see any effect of cAMP-GEF activation or direct GSK inhibition on this event. However, since BAX activation requires not only translocation to mitochondria, but also a conformational change and integration into the mitochondrial membrane (21), our studies do not preclude a role for GSK inhibition in cAMP-GEF/GSK3␤ cytoprotection. Indeed in nonhepatic cells GSK inhibition has been reported to prevent BAX conformation changes and thus prevent its proapoptotic action (49) . This is an area that will require additional study.
The finding that increasing cAMP results in PI3K-and PKA-dependent phosphorylation of GSK has implications beyond bile acid-induced hepatobiliary disease. GSK has a prominent role in carbohydrate and lipid metabolism (20, 29, 70) . Traditionally, increases in cAMP that occur downstream of glucagon signaling in hepatocytes were felt to be anti-insulin. However, this may be an oversimplification since we show that cAMP itself can trigger PI3K/Akt-dependent activation of GSK similar to insulin. It is possible that the insulin-and cAMP-dependent PI3K/Akt/GSK pathways differentially modulate separate pools of GSK leading to divergent downstream events. This phenomenon has been demonstrated for adrenaline signaling in skeletal muscle (36) . GSK is a known as a promiscuous kinase whose downstream actions are mediated in a cell-and stimulus-specific manner (7, 8, 36, 38) . GSK's signaling is made more complex in that all GSK substrates must be primed by phosphorylation by another kinase for GSK recognition (20, 38, 70) . Future experiments to determine the downstream events controlled by cAMP/PKA/ GSK3␤ and cAMP-GEF/PI3K/Akt/GSK3␤ pathways in hepatocytes are needed.
Dysregulation of GSK is implicated in various human disease processes including cardiac myocyte ischemic injury, neurogeneration, and diabetes mellitus (2, 28, 29, 58, 88) . The investigation of the role of GSK3 in hepatobiliary disorders is still in its early stages. In previous studies GSK inhibition has been implicated in ischemia-reperfusion, endotoxin, free fatty acid, and acetaminophen-mediated cell death in hepatocytes (17, 35, 78, 87) . We now report its association with bile acid-induced apoptosis in hepatocytes and thus its possible role in hepatocyte cell death during cholestatic liver injury.
GSK inhibitors are currently under development for their therapeutic potential in neuronal and cardiac disease (2, 29, 68, 88) . These inhibitors and/or targeting of GSK inactivation with cAMP-GEF analogs may also have therapeutic potential in hepatobiliary disease. GSK inhibition may ultimately be a better way to intercept proapoptotic JNK signaling pathway than direct targeting of JNK. Numerous studies have documented the pathological significance of sustained JNK signaling in hepatocyte cell death. Thus inhibition of bile acid-induced JNK activation should be cytoprotective. In the liver JNK is encoded by two genes, JNK1 and JNK2. Studies using genetic strategies to inactivate the JNK isoforms or in mice with knockdown of either JNK1 and/or JNK2 have shown distinct and often opposing functions of JNK1 and JNK2 in hepatocyte injury depending on the pathological stress (27, 40, 42, 47, 69, 84, 85, 91) . The molecular basis for these differences are not well characterized. It does appear, however, that for clinical application JNK isoform-specific inhibitors will be necessary. The currently available JNK inhibitors (SP600125 and AS601645), however, are not isoform specific. In contrast to JNK inhibition, GSK inhibition seems to have a consistent hepatoprotective effect, and although most GSK inhibitors work on both GSK␣ and GSK␤, there is no literature to support the observation that they have opposing effects in cell death (1, 2, 15, 20, 30, 34, 35, 41, 48, 58, 68, 78, 87, 90) . Thus inhibition of GSK3␤ may be a more targeted way to decrease JNK activation. Moreover, since GSK is involved in the pathogenesis of other human disease including Type II diabetes, cardiac myocyte ischemia, Alzheimers disease, and stroke, there is already a significant body of information showing the preclinical efficacy of GSK inhibitors in in vivo models (2, 17, 58, 88) .
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